Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates™: NCCN Guidelines® & NCCN Compendium Updated®

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Myeloid Growth Factors. These NCCN Guidelines® are currently available as Version 1.2016.

  • Prophylactic use of granulocyte colony-stimulating factors (G-CSF)
    • Footnote “d” has been added to define “G-CSF” as used in the guidelines: “G-CSF refers to the following approved agents: filgrastim, filgrastim-sndz, tbo-filgrastim, and pegfilgrastim. See G-CSF for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery (MGF-B).” (MGF-1)
    • For intermediate-risk (10- 20% risk of developing febrile neutropenia) patients with solid tumors and nonmyeloid malignancies receiving treatment in the curative/adjuvant or palliative settings, the panel recommends consideration of prophylactic G-CSF based on patient risk factors. A patient risk factor assessment has been added to the algorithm. (MGF-2) 
    • Sargramostim has been removed from the list of recommended prophylactic MGF options. (MGF-B, 1 of 2)


  • Therapeutic Use of Myeloid Growth Factors (MGF)
    • For patients who present with febrile neutropenia, it has been clarified that the recommendation to continue G-CSF applies to those who received prophylactic filgrastim, filgrastim-sndz, or tbo-filgrastim. (MGF-4)
    • A list of MGF recommended for therapeutic use has been added, including scheduled dose delivery. (MGF-C)


  • MGF in Mobilization and Post Hematopoietic Cell Transplant (MGF-D)
    • Tbo-filgrastim has been added for the following indications:
      • As a single agent option for mobilization in the autologous setting.
      • With a goal of mobilization during count recovery following combination chemotherapy.
      • In combination with plerixafor in the autologous setting.
      • As a single agent option for mobilization of allogeneic donors (category 2B).
      • For granulocyte transfusion (category 2B).
      • As a single agent option for supportive care post autologous hematopoietic cell or cord blood transplant.
    • "Concurrent filgrastim/filgrastim-sndz + sargramostim" has been changed to a category 2B recommendation for the mobilization of hematopoietic progenitor cells in the autologous setting. 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Compendium®, and the NCCN Chemotherapy Order Templates (NCCN Templates®), please visit NCCN.org.

To access the NCCN Biomarkers Compendium™, please visit NCCN.org/biomarkers.

To view the NCCN Guidelines for Patients®, please visit NCCN.com/patients.

Free NCCN Guidelines apps for iPhone, iPad, and Android tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

National Comprehensive Cancer Network® (NCCN®)

275 Commerce Drive, Suite 300

Fort Washington, PA 19034

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2016 National Comprehensive Cancer Network. All Rights Reserved.